Article thumbnail

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

By Debora Williams-Herman, Samuel S Engel, Elizabeth Round, Jeremy Johnson, Gregory T Golm, Hua Guo, Bret J Musser, Michael J Davies, Keith D Kaufman and Barry J Goldstein
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3161395
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2007). Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care
  2. (2007). AG: Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA
  3. (2007). Agency (EMEA): Galvus (vildagliptin) - European Public Assessment Report (EPAR) - Scientific Discussion
  4. (2007). Agency (EMEA): Januvia (sitagliptin) - European Public Assessment Report (EPAR) - Scientific Discussion
  5. (2009). Agency (EMEA): Onglyza (saxagliptin) - European Public Assessment Report (EPAR) - CHMP Assessment Report
  6. (2008). CL: Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev
  7. (1985). Comparative analysis of two rates. Stat Med
  8. (2008). CR: Use of thiazolidinediones and fracture risk. Arch Intern Med
  9. Day NE: Statistical methods in cancer research. Volume II--The design and analysis of cohort studies.
  10. (2007). DE: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care
  11. (2007). Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol
  12. (2008). Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension
  13. (2009). Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension
  14. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
  15. (2006). Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care
  16. (2009). Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin
  17. (2010). Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab
  18. (2008). Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin
  19. (2010). Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab
  20. (2009). Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract
  21. (2010). Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab
  22. (2006). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care
  23. (2006). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallelgroup study. Clin Ther
  24. (2006). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia
  25. (2007). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab
  26. (2007). Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.
  27. (1986). Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics
  28. (2007). et al.: Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes
  29. (2009). Gale EA: Does diabetes therapy influence the risk of cancer? Diabetologia
  30. (2009). GLP-1: broadening the incretin concept to involve gut motility. Regul Pept
  31. (1970). Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adultonset diabetes. Mortality results. Diabetes
  32. (2010). Guidance for Industry: Collection of race and ethnicity data in clinical trials.
  33. (2008). Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol
  34. (2009). Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol
  35. (2009). Initial combination therapy with sitagliptin and pioglitazone: complementary effects on postprandial glucose and islet cell function (abstract). IDF Abstract Book
  36. (2008). Inzucchi SE: New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications. Circulation
  37. (2009). JM: Thiazolidinediones and fractures in men and women. Arch Intern Med
  38. (2009). Mannucci E: Dipeptydil peptidase4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis
  39. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
  40. (2008). New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation
  41. (2002). Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA
  42. (2007). PP: Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin
  43. (2008). PP: Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin
  44. (2009). Radke F: Benign skin lesions: lipomas, epidermal inclusion cysts, muscle and nerve biopsies. Surg Clin North Am
  45. RR: Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (abstract). Diabetologia 2009, 52(Suppl 1):S480.
  46. (2008). Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab
  47. (2010). Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study.
  48. (2008). Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord
  49. (2008). Sitagliptin monotherapy is an effective and well-tolerated treatment for type 2 diabetes in elderly patients (abstract). 61st Annual Scientific Meeting of the Gerontological Society of America
  50. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
  51. (2008). SS: Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab
  52. (2007). The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology
  53. Thiazolidinediones, but not sitagliptin, exacerbate ovariectomyinduced bone loss in rats (abstract). Diabetes 2009, 58(Suppl 1):A374.
  54. Triple combination therapy with sitagliptin, metformin, and rosiglitazone improves glycemic control in patients with type 2 diabetes (abstract). Diabetes 2008, 57(Suppl 1):A595-A596.